Hexarelin for Men: What the Studies in Men Measured, and What to Check First

A 2001 comparison in the Journal of Clinical Endocrinology and Metabolism gave healthy young men ghrelin, hexarelin and GHRH on separate days. Ghrelin released the most growth hormone, hexarelin the next most, GHRH the least, and hexarelin and ghrelin did not add to each other, as expected for two ligands at the same receptor.

What it shows. That hexarelin makes a young male pituitary release a large pulse of its own growth hormone.

What it does not show. Anything downstream of that pulse. It measured hormones on single days.

A 2002 study in the European Journal of Endocrinology gave six young men two or three subcutaneous injections across a day. Either schedule raised 24-hour growth hormone secretion by enlarging each pulse without changing how often pulses came, and did not alter 24-hour prolactin, ACTH or cortisol.

What it shows. That subcutaneous hexarelin, the route prescribed today, works in men, and that the cortisol and prolactin rise with each dose does not add up to a higher daily total.

What it does not show. Anything beyond one day, or any effect on body composition, sleep or recovery.

In the Journal of Endocrinological Investigation in 1999, seven male volunteers had left ventricular ejection fraction measured after hexarelin and, separately, after recombinant growth hormone. Hexarelin raised ejection fraction from 64 to about 71 percent for roughly an hour, with no change in blood pressure or heart rate; growth hormone did not. In the European Journal of Pharmacology in 2002, twenty-four men with coronary artery disease received hexarelin, GHRH, growth hormone or placebo during bypass surgery; only hexarelin raised ejection fraction, cardiac index and cardiac output, from ten to ninety minutes.

What it shows. A short-lived effect on the heart's contractility that does not run through growth hormone.

What it does not show. Any benefit from ongoing subcutaneous use. Every human cardiac study used a single intravenous dose, and none measured a clinical outcome. Hexarelin is not a heart medication.

The most important paper for anyone considering a course is the 1998 study in the Journal of Clinical Endocrinology and Metabolism. Healthy elderly volunteers took twice-daily subcutaneous hexarelin for sixteen weeks. The growth hormone response to a test dose fell by nearly half by week sixteen and returned to baseline four weeks after stopping. IGF-1, total body fat, lean body mass and bone mineral density did not change significantly; one marker of collagen formation rose. The live summary does not break the results down by sex.

The growth hormone response is smaller in older adults: a 1994 paper reported it blunted in the elderly and restored by arginine or GHRH, and a 1997 paper in the European Journal of Endocrinology described the growth hormone, prolactin, ACTH and cortisol responses each changing differently with age. It is also blunted in obesity. A man in his fifties should not expect the pulse measured in a twenty-five-year-old.

This is the most common misunderstanding. Hexarelin acts on the growth hormone axis. It is not an anabolic steroid, does not bind the androgen receptor, and does not raise or suppress testosterone. Low testosterone on two morning blood draws with symptoms is hypogonadism, which is treated with testosterone under its own monitoring, not with a secretagogue. The comparison is in peptides for testosterone and peptides vs TRT and steroids.

Men on testosterone replacement often ask about adding a growth hormone peptide. What makes it reasonable is that every prescriber involved knows about the other. Growth hormone reduces insulin sensitivity, and hexarelin adds a cortisol pulse, so glucose is the thing to watch when both axes are engaged. List your testosterone prescription on the intake and tell whoever manages your TRT what you are adding. Can you take peptides with testosterone covers the detail.

Hexarelin acts on the growth hormone axis rather than the reproductive axis, and no study in the live research has measured fertility outcomes with it. That is an absence of data, not a finding either way. If you are trying to conceive, say so on the intake. Do peptides affect fertility covers the conversation.

Each dose raises prolactin briefly; the 1997 study in Peptides found the rise smaller than that from TRH, and 24-hour prolactin did not change in the 2002 study of young men. Anyone with a known prolactin-related condition should raise it at intake, because hexarelin is not the first choice for conditions sensitive to that hormone.

The acute cardiac effect is real and was measured in men. It is described as protective in animal work, but no study has looked at ongoing use in men with heart disease. A cardiac diagnosis belongs on the intake rather than being assumed to be a reason to take it.

Anything that raises growth hormone and IGF-1 carries the class cautions in approved growth hormone labelling: glucose intolerance, fluid retention and a theoretical concern about existing tumours. No data show hexarelin is exempt. A personal history of cancer, including prostate cancer, and any diabetes or impaired glucose tolerance go on the intake in full.

Men bring sleep and recovery complaints to growth hormone peptides more than anything else. A 2000 study in JAMA found slow-wave sleep and growth hormone secretion declining together in healthy men from early adulthood, which is the rationale for a bedtime dose, not evidence that a dose restores sleep. Obstructive sleep apnea, evening alcohol and an inconsistent wake time degrade deep sleep on their own. Peptides for men over 40 sets out what a physician looks at first.

The 2026 WADA Prohibited List names examorelin, which is hexarelin, among growth-hormone-releasing peptides under S2.2.4, prohibited at all times, and the 2027 List keeps it there. A prescription does not create an exemption. See is hexarelin banned in sports.